BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29520587)

  • 1. P-glycoprotein Restricts Ocular Penetration of Loperamide across the Blood-Ocular Barriers: a Comparative Study in Mdr1a Knock-out and Wild Type Sprague Dawley Rats.
    Tatke A; Janga KY; Avula B; Wang X; Jablonski MM; Khan IA; Majumdar S
    AAPS PharmSciTech; 2018 May; 19(4):1662-1671. PubMed ID: 29520587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retina Compatible Interactions and Effective Modulation of Blood Ocular Barrier P-gp Activity by Third-Generation Inhibitors Improve the Ocular Penetration of Loperamide.
    Janga KY; Tatke A; Shukla S; Lamichhane SP; Avula B; Wang X; Jablonski MM; Khan IA; Majumdar S
    J Pharm Sci; 2018 Aug; 107(8):2128-2135. PubMed ID: 29678592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
    Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
    Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Competitive substrates for P-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and loperamide: pharmacokinetics and pharmacodynamics in Sprague-Dawley rats.
    Elkiweri IA; Zhang YL; Christians U; Ng KY; Tissot van Patot MC; Henthorn TK
    Anesth Analg; 2009 Jan; 108(1):149-59. PubMed ID: 19095843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
    Zamek-Gliszczynski MJ; Bedwell DW; Bao JQ; Higgins JW
    Drug Metab Dispos; 2012 Sep; 40(9):1825-33. PubMed ID: 22711747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibition protects blood-brain barrier P-glycoprotein and lowers Aβ brain levels in an Alzheimer's disease model.
    Vulin M; Zhong Y; Maloney BJ; Bauer B; Hartz AMS
    Fluids Barriers CNS; 2023 Oct; 20(1):70. PubMed ID: 37803468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib.
    Choo EF; Ly J; Chan J; Shahidi-Latham SK; Messick K; Plise E; Quiason CM; Yang L
    Mol Pharm; 2014 Nov; 11(11):4199-207. PubMed ID: 25243894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential role of P-glycoprotein and breast cancer resistance protein in drug distribution into brain, CSF and peripheral nerve tissues in rats.
    Huang L; Li X; Roberts J; Janosky B; Lin MH
    Xenobiotica; 2015; 45(6):547-55. PubMed ID: 25539457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of P-glycoprotein on blood-retinal barrier permeability: comparison of blood-aqueous humor and blood-brain barrier using mdr1a knockout rats.
    Fujii S; Setoguchi C; Kawazu K; Hosoya K
    Invest Ophthalmol Vis Sci; 2014 Jul; 55(7):4650-8. PubMed ID: 24985475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the polymorphic efflux transporter P-glycoprotein on the brain accumulation of d-methylphenidate and d-amphetamine.
    Zhu HJ; Wang JS; DeVane CL; Williard RL; Donovan JL; Middaugh LD; Gibson BB; Patrick KS; Markowitz JS
    Drug Metab Dispos; 2006 Jul; 34(7):1116-21. PubMed ID: 16621932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures.
    Venkatakrishnan K; Tseng E; Nelson FR; Rollema H; French JL; Kaplan IV; Horner WE; Gibbs MA
    Drug Metab Dispos; 2007 Aug; 35(8):1341-9. PubMed ID: 17470526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of mass of [11C]-laniquidar and [11C]-N-desmethyl-loperamide on P-glycoprotein blockage at the blood-brain barrier.
    Moerman L; Dumolyn C; Boon P; De Vos F
    Nucl Med Biol; 2012 Jan; 39(1):121-5. PubMed ID: 21958857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging P-glycoprotein function in rats using [(11)C]-N-desmethyl-loperamide.
    Farwell MD; Chong DJ; Iida Y; Bae SA; Easwaramoorthy B; Ichise M
    Ann Nucl Med; 2013 Aug; 27(7):618-24. PubMed ID: 23572210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier.
    Yu XY; Lin SG; Chen X; Zhou ZW; Liang J; Duan W; Chowbay B; Wen JY; Chan E; Cao J; Li CG; Zhou SF
    Curr Drug Metab; 2007 May; 8(4):365-78. PubMed ID: 17504224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of loperamide as a phenotypic probe of mdr1a status in CF-1 mice.
    Kalvass JC; Graff CL; Pollack GM
    Pharm Res; 2004 Oct; 21(10):1867-70. PubMed ID: 15553234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of P-glycoprotein and multidrug resistance associated protein 1 in the transport of tanshinone IIB, a primary active diterpenoid quinone from the roots of Salvia miltiorrhiza, across the blood-brain barrier.
    Zhou ZW; Chen X; Liang J; Yu XY; Wen JY; Zhou SF
    Drug Metab Lett; 2007 Aug; 1(3):205-17. PubMed ID: 19356045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists.
    Chen C; Hanson E; Watson JW; Lee JS
    Drug Metab Dispos; 2003 Mar; 31(3):312-8. PubMed ID: 12584158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of p-glycoprotein on brain Bcl-2 family proteins and cytokines in transient cerebral ischemia.
    Murozono M; Kobayashi T; Sekine S; Kakinuma T
    Neuro Endocrinol Lett; 2020 Dec; 41(5):231-238. PubMed ID: 33315338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ketoconazole on the biodistribution and metabolism of [11C]loperamide and [11C]N-desmethyl-loperamide in wild-type and P-gp knockout mice.
    Seneca N; Zoghbi SS; Shetty HU; Tuan E; Kannan P; Taku A; Innis RB; Pike VW
    Nucl Med Biol; 2010 Apr; 37(3):335-45. PubMed ID: 20346873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable modulation of opioid brain uptake by P-glycoprotein in mice.
    Dagenais C; Graff CL; Pollack GM
    Biochem Pharmacol; 2004 Jan; 67(2):269-76. PubMed ID: 14698039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.